Every 10-Q that Certara, Inc. (CERT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CERT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CERT filings page.
Certara, Inc. reported Q2 2026 revenue of $93,271, up from $92,356 a year earlier, but continuing operations shifted to a loss of $6,081 from income of $1,496 as higher operating expenses and interest exceeded revenue.
The company completed the sale of its Regulatory and Medical Writing business to Veristat, receiving $69,435 in cash, with $15,000 in escrow and an earn-out of up to $35,000. The transaction generated a pre-tax disposal loss of $65,481 and contributed to a Q2 net loss attributable to common stockholders of $55,270, or $0.36 per share, versus a $1,968 loss in 2025.
Cash and cash equivalents were $184,138 at June 30, 2026, against term loans of $294,028 and total liabilities of $433,283. Operating activities provided $21,732 in cash in the first half, while the divestiture drove $54,960 of net investing inflows. The company used $57,389 under its repurchase program in the first six months, and as of August 1, 2026, there were 152,538,780 common shares outstanding.
Certara, Inc. reported flat revenue but a swing to loss in its latest quarter. For the three months ended March 31, 2026, revenue was $106.9 million, up slightly from $106.0 million a year earlier, while net results moved from $4.7 million profit to a $8.8 million loss, or basic and diluted loss of $0.06 per share.
Operating income declined to a $4.3 million loss as general and administrative and research and development expenses increased. Cash and cash equivalents fell from $189.4 million at year-end to $149.5 million, driven largely by $40 million of share repurchases and ongoing investment in software development.
The company ended the quarter with $294.8 million of term-loan debt and total stockholders’ equity of $1.02 billion. Bookings were $115.3 million with a software net retention rate of 106.1%, indicating expansion within the existing customer base. After quarter end, Certara closed the sale of its global medical writing and related regulatory services business, expecting to recognize a loss estimated between $28.9 million and $53.7 million on that divestiture.
Certara, Inc. reported continued growth in Q3 2025. Revenue for the quarter reached $104.6 million, up from $94.8 million a year ago, and year‑to‑date revenue rose to $315.2 million from $284.8 million. The company posted quarterly net income of $1.5 million versus a loss last year, and year‑to‑date net income of $4.3 million compared with a prior-year loss. Gross cost trends remained controlled as operating expenses rose modestly alongside higher sales.
Cash generation strengthened and the balance sheet remained liquid. Cash and cash equivalents were $172.7 million as of September 30, 2025. Net cash provided by operating activities was $67.5 million year‑to‑date, more than double the prior year. Term loans stood at $296.3 million, with an effective rate of 7.39% year‑to‑date. The company executed share repurchases of $38.7 million in 2025, increasing treasury stock to 4,477,064 shares. Revenue mix showed software licenses and services both contributing, while deferred revenue was $65.9 million, supporting near‑term visibility. Interest rate risk is hedged with swaps totaling $230.0 million notional maturing in 2029.